AMR Crisis Experts See Hopeful Signs For 2020
But Worries Rise US Politics May Stop Needed Progress
2020 could be a watershed year in tackling AMR, but success needs market reforms that ensure new antibiotics get to market and prevent innovators going bust, experts tell Scrip.
You may also be interested in...
Designers of the UK’s experimental antibiotic payment system aim to identify two drugs later this year which will then undergo a novel technology assessment in 2021.
Antimicrobial specialist Destiny Pharma aims to enlist a pharma partner later this year to help advance and launch its lead asset for preventing post-surgical infections.
Antibiotics specialist Antabio aims to get enough funding to advance its pipeline far enough to become a takeover target.